Avalon Capital Management’s AbbVie ABBV Stock Holding History

Avalon Capital Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-19,907	Closed	-$1.84M	–	47
2018 Q2	$1.84M	Sell	19,907 -400	-2%	-$39.1K	1.83%	19
2018 Q1	$1.92M	Sell	20,307 -20	-0.1%	-$2.2K	1.89%	16
2017 Q4	$1.97M	Sell	20,327 -4,481	-18%	-$422K	1.76%	18
2017 Q3	$2.2M	Sell	24,808 -850	-3%	-$64.7K	1.53%	19
2017 Q2	$1.86M	Sell	25,658 -340	-1%	-$22.9K	1.37%	25
2017 Q1	$1.69M	Sell	25,998 -800	-3%	-$50.3K	1.17%	32
2016 Q4	$1.68M	Sell	26,798 -600	-2%	-$36.6K	1.28%	29
2016 Q3	$1.73M	Hold	27,398	–	–	1.33%	29
2016 Q2	$1.7M	Buy	+27,398	New	+$1.67M	1.33%	31
2014 Q1	–	Sell	-24,376	Closed	-$1.29M	–	94
2013 Q4	$1.29M	Buy	24,376 +4,805	+25%	+$236K	1.09%	29
2013 Q3	$875K	Sell	19,571 -100	-0.5%	-$4.43K	0.86%	36
2013 Q2	$813K	Buy	+19,671	New	+$860K	0.8%	40

Other funds holding ABBV

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Avalon Capital Management's ABBV Position: Q3 2018 in Review

Avalon Capital Management sold out of AbbVie (ABBV) in Q3 2018, closing a stake of 19,907 shares — an estimated $1.84M sold.

Avalon Capital Management first reported a position in ABBV in Q2 2013 and held it in 12 quarters. The position peaked at $2.2M in Q3 2017. 1,956 funds tracked by Wall St. Rank hold ABBV as of Q3 2018.

Avalon Capital Management reported no remaining AbbVie position as of Q3 2018 after selling out during the quarter.
Avalon Capital Management sold 19,907 AbbVie shares in Q3 2018, an estimated $1.84M.
Avalon Capital Management first reported a position in AbbVie in Q2 2013 and held it in 12 quarters.
Avalon Capital Management's AbbVie position peaked at $2.2M in Q3 2017.
1,956 funds tracked by Wall St. Rank held AbbVie as of Q3 2018.

Based on Avalon Capital Management's 13F filing for Q3 2018, filed 18 Oct 2018.